Clinical Trials Logo

Filter by:
NCT ID: NCT00754884 Withdrawn - Fibromyalgia Clinical Trials

Calcitonin in the Treatment of Fibromyalgia

CALFI
Start date: October 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether nasal administration of salmon calcitonin is effective and safe in the treatment of symptoms and signs of primary fibromyalgia.

NCT ID: NCT00600301 Withdrawn - Clinical trials for Diffuse Diabetic Macular Edema

Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study

Start date: January 2008
Phase: Phase 3
Study type: Interventional

Diabetic macular edema is the most common cause of visual loss among patients with diabetic retinopathy. Pars plana vitrectomy has been reported to be effective for the treatment of diabetic macular edema. Previous report showed a limited improvement in visual acuity and macular thickness posterior intraoperative triamcinolone acetonide. Bevacizumab intravitreal injection has been proven be effective in the treatment of diabetic macular edema, in recent publications. The purpose of this study is to evaluate whether vitrectomy with and without intravitreal triamcinolone acetonide and bevacizumab injection affects vision outcome and macular thickness in patients with diabetic macular edema.

NCT ID: NCT00600236 Withdrawn - Clinical trials for Diabetes Mellitus Type 2

HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population

Start date: September 2004
Phase: Phase 3
Study type: Interventional

One of the first causes of irreversible blindness in mexican population is diabetic retinopathy which is clearly diferent between patients the time of evolution and development of retinopathy and complications. The aim of this study is to explore the inmunogenetic profile and the influence of HLA in this variations of the sickness to predict the severity of diabetic complications.

NCT ID: NCT00567372 Withdrawn - Clinical trials for Diffuse Diabetic Macular Edema

POSTERIOR SUB-TENON'S Avastin

Start date: June 2008
Phase: Phase 4
Study type: Interventional

Posterior sub-tenon's injection of bevacizumab decreased diffuse diabetic macular edema

NCT ID: NCT00563121 Withdrawn - Clinical trials for Retinopathy of Prematurity

VEGF Levels in Aqueous, Vitreous and Subretinal Fluid in ROP Stage IV and V

Start date: March 2007
Phase: Phase 4
Study type: Interventional

To determine the degree of VEGF in Aqueous, vitreous and SRF in patients with ROP in stage V. Verifying that it is greater to that found in healthy newborn patients with different ocular pathology.

NCT ID: NCT00517491 Withdrawn - Acromegaly Clinical Trials

Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)

Start date: May 2008
Phase: Phase 2
Study type: Interventional

The purpose of the protocol is to evaluate the correlation between plasma lanreotide levels and Growth Hormone (GH)/Insulin Like Growth Factor 1 (IGF-1) dynamics and clinical improvement in patients with acromegaly treated with lanreotide Autogel (Somatuline ATG)

NCT ID: NCT00499551 Withdrawn - Uveitis Clinical Trials

A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis

Start date: September 2007
Phase: Phase 1/Phase 2
Study type: Interventional

The multiple properties of the corticosteroids over the inflammatory response, make them first line drugs for the treatment of several ocular inflammatory disorders of different etiologies. In order to diminish the corticosteroids severe systemic adverse effects, the local administration is preferred. Iontophoresis already has been used in a successful way for the administration of corticosteroids. Clinical or histopathological injuries due to the use of transcleral CCI have not been observed. being successful the administration of methylprednisolone by means of this system in previous studies. The objective is to evaluate the tolerance, security and effectiveness of this treatment, using a new generation device.

NCT ID: NCT00496405 Withdrawn - Clinical trials for Diabetic Retinopathy

Unilateral Bevacizumab for Bilateral Diabetic Macular Edema

Start date: April 2007
Phase: Phase 4
Study type: Interventional

The endothelial growth factor (VEGF), has been implied in the genesis of diverse Neovascular disease. In the industrialized and developing countries, the main cause of blindness is the diabetic retinopathy. Bevacizumab (Avastin, genentech, Inc., San Francisco, California, the USA) is a drug.In the last years its use "off-label", in ophthalmology field, has become popular. This is due to its proven safeness and effectiveness for the treatment of diverse ocular diseases. A lot has been speculated about the systemic absorption of Bevacizumab. It is for that reason that the objective of this study is the systematic and random revision of the fellows eyes, of the patients programmed for the intravitreal administration of Bevacizumab, with bilateral macular edema. In such a way that the therapeutic value in the fellow eye of bevacizumab can be determined

NCT ID: NCT00418431 Withdrawn - Clinical trials for Central Serous Chorioretinopathy

Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy

Start date: April 2006
Phase: Phase 2/Phase 3
Study type: Interventional

Central serous chorioretinopathy (CSC) has been known since it was first described by Von Graefe and termed "idiopathic detachment of the macula" in 1866, is a well-characterized disorder leading to serous neurosensory elevation of the central macula. The acute form of the disease is associated with focal leakage at the level of the retinal pigment epithelium (RPE) demonstrated with fluorescein angiography (FA). The disorder is self-limited in the majority of patients, who also regain excellent vision. Occasionally, the neurosensory detachment persists and leads to pigment epithelial and photoreceptor damage with visual impairment. The purpose of this clinical study is report the use of intravitreal bevacizumab is a new option in the treatment of the chronic or recurrent CSC.

NCT ID: NCT00417716 Withdrawn - Clinical trials for Diabetic Macular Edema

Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema

Start date: September 2005
Phase: Phase 3
Study type: Interventional

Intravitreal Bevacizumab is an effective treatment for the diffuse diabetic macular edema